Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chubb
Johnson and Johnson
Queensland Health
Cantor Fitzgerald
Teva
Farmers Insurance
Medtronic
Accenture

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLUOXETINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Fluoxetine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00000213 IV Cocaine Abuse: A Laboratory Model - 2 Completed Columbia University Phase 2 The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.
NCT00000213 IV Cocaine Abuse: A Laboratory Model - 2 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.
NCT00000213 IV Cocaine Abuse: A Laboratory Model - 2 Completed New York State Psychiatric Institute Phase 2 The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.
NCT00000373 Treatment of Obsessive-Compulsive Disorder Completed National Institute of Mental Health (NIMH) Phase 4 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 Treatment of Obsessive-Compulsive Disorder Completed University of Florida Phase 4 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Fluoxetine Hydrochloride

Condition Name

Condition Name for Fluoxetine Hydrochloride
Intervention Trials
Depression 41
Major Depressive Disorder 35
Bipolar Disorder 10
Healthy 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Fluoxetine Hydrochloride
Intervention Trials
Depression 105
Depressive Disorder 89
Depressive Disorder, Major 59
Disease 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Fluoxetine Hydrochloride

Trials by Country

Trials by Country for Fluoxetine Hydrochloride
Location Trials
United States 382
Canada 14
France 13
Mexico 8
China 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Fluoxetine Hydrochloride
Location Trials
New York 42
California 26
Pennsylvania 21
Texas 20
Massachusetts 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Fluoxetine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Fluoxetine Hydrochloride
Clinical Trial Phase Trials
Phase 4 70
Phase 3 37
Phase 2/Phase 3 5
[disabled in preview] 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Fluoxetine Hydrochloride
Clinical Trial Phase Trials
Completed 138
Recruiting 33
Unknown status 15
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Fluoxetine Hydrochloride

Sponsor Name

Sponsor Name for Fluoxetine Hydrochloride
Sponsor Trials
National Institute of Mental Health (NIMH) 39
Eli Lilly and Company 14
New York State Psychiatric Institute 12
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Fluoxetine Hydrochloride
Sponsor Trials
Other 273
Industry 71
NIH 59
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
QuintilesIMS
US Army
Harvard Business School
Fish and Richardson
Cantor Fitzgerald
Colorcon
McKesson
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.